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Introduction
Medication errors contribute significantly to human and financial 
costs.1-4 One of these errors involves incorrect identification 
of concentrated potassium chloride ampoules. After coronary 
artery bypass grafting, potassium concentrations lower and 
higher than 3.3 and 5.2 mmol per liter respectively have been 
associated with poorer outcome.5 Maintaining adequate 
levels frequently requires potassium administration by 
anesthesiologists. Indeed, the Joint Commission and similar 
National organizations have classified concentrated potassium 
chloride as a high alert medication.6-14 One reason for this 
classification is that the intravenous injection of concentrated 
potassium confused with sodium chloride or water to constitute 
antibiotics or flush intravenous catheters has resulted in 
death.15-17 Recently, ampoule similarity resulted in accidental 
subarachnoid injection of concentrated potassium instead 
of bupivacaine.18 Typical safety guidelines have included the 
removal of concentrated potassium ampoules from clinical areas 
and storage only within certain locations (pharmacy, Intensive 
Care Units and operating rooms), storage within a locked 
cupboard as for controlled substances, supplying premixed 
potassium containing bags, using easily distinguishable 
packaging and labels for bags and ampoules, specifying on-
site preparation protocols, and administration using volumetric 
pumps.9,11,17,19,20 It has been argued that while safety guidelines 
to ensure potassium administration errors “never occur again” 
are logical,21 they are not backed by objective evidence of 
efficacy.22 Safety guidelines may have unexpected effects on the 
functioning of healthcare systems and could instigate “the next 
error by trying to prevent the last one”.15,23 In this regard, a local 
distributor of 15% potassium chloride has printed instructions 
in red type on both the box and each ampoule (Figure 1) that 
contents must be diluted with more than fifty times its volume 
before use. However, in developing countries concentrated 
potassium solutions for point of care dilution are still available in 
operating rooms and critical care areas. 
Our department was consulted by forensic pathology about 
a hyperkalemic arrest following combined open prosthetic 
aortic valve insertion and coronary artery bypass grafting at 
a hospital in another province. The anesthesiologists’ report 
described difficult weaning from cardiopulmonary bypass 
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Abstract: 
Background: This study investigated maldistribution of concentrated 15% potassium chloride after injection into one-liter, flexible, 
Ringer’s lactate bags. 
Methods: Twenty milliliters of concentrated 15% potassium chloride was injected into suspended, flexible, liter bags of Ringer’s 
lactate. The potassium was injected by hand, over either four (“fast”) or twenty (“slow”) second periods. The effect of two successive 
bag inversions on maldistribution was also investigated. A simulated infusion at 600 ml per hour was controlled using a volumetric 
pump. Sampling occurred at 5-minute intervals for the first 20 minutes and at 10-minute intervals thereafter until 90 minutes. 
Potassium concentrations were measured using an accurate, calibrated wide range analyzer not requiring specimen dilution. This 
experiment was repeated once. A duplicate set of experiments was performed with Bonney’s blue dye added to the potassium 
concentrate. Bonney’s blue distribution was evaluated visually.
Results: Significant maldistribution occurred. Maldistribution was not dependent on the injection rate. After 20 to 30 minutes of 
commencing the infusion, maldistribution resulted in delivery of up to 64 to 85% respectively of the available potassium. Two bag 
inversions effectively homogenised the solution. The distribution of Bonney’s blue stained concentrated potassium was inconsistent 
with measured potassium concentrations.
Conclusions: In cardiac and other surgery, point of care potassium supplementation is frequently required. Anaesthetists should 
be cognisant of eliminating not only errors of substitution, but also maldistribution of concentrated potassium. Potassium infusion 
rates should be controlled, preferably using an electronic infusion controller.
Keywords: potassium, hyperkalemia, anaesthesia related death, drug error, maldistribution, layering, complication, preventable, 
mixing, homogenization, mortality, magnesium, dye, indicator, mistake
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and detailed potassium concentrations of 4.7 and 3.9 mmol/L 
immediately before and after successful weaning from bypass 
respectively. After bypass, forty millimoles of concentrated 
15% potassium chloride (Sabax, Adcock Ingram Critical Care, 
Johannesburg, South Africa) were injected into a full liter of 
Ringer’s lactate and infused using a gravity dependent infusion 
controller at approximately 600 ml/hour. Twenty minutes 
after commencement of the infusion, asystole occurred with 
serum potassium of 16.1 mmol/L measured during successful 
resuscitation. 
We considered the hyperkalemia might have been caused by 
maldistribution of the concentrated potassium added to the 
Ringer’s lactate. Notwithstanding older descriptions,24-28 we re-
investigated this phenomenon.
Methods
We designed a series of blinded, randomized, controlled, 
laboratory experiments to mimic the index scenario, which 
interrogated factors influencing concentrated potassium 
distribution after addition to Ringer’s lactate. Institutional 
ethics committee approval was obtained (protocol number 
S13/05/107). Our null hypothesis was that in the absense of 
purposeful mixing, concentrated 15% potassium chloride 
solution distributes evenly after injection into a compressible 
liter bag of Ringer’s lactate solution. Twenty milliliters of 
concentrated 15% potassium chloride (Sabax, Adcock Ingram 
Critical Care, Johannesburg, South Africa) was injected via the 
dependent injection port into a suspended, one liter (Viaflex®) 
Ringer’s lactate container (Adcock Ingram Critical Care under 
license from Baxter International Inc., Johannesburg, South 
Africa). Each injection was performed using a new 20 ml syringe 
(Surgiplus®, China) attached to a new 18 gauge, 40 millimeter 
long, hypodermic injection needle (Surgiplus®, China) inserted 
into the 40 mm injection port of the Ringer’s lactate container. 
The concentrated potassium was manually injected either 
“slowly” over approximately 20 seconds (1ml/s) or “rapidly” over 
4 seconds (5ml/s). One “slow” injection bag was purposefully 
mixed, the bag being inverted twice over 2 seconds. The control 
was a liter bag of Ringer’s lactate to which 20 ml of normal 
saline had been added over 4 seconds. Braun Infusomat® FM 
pumps (Infusomat fmS, B Braun Melsungen AG, Melsungen, 
Germany) using Infusomat® tubing set (TK 200) were used to 
control the infusion rate at 600 ml per hour. The infusion set 
was primed before addition of solute to the Ringer’s lactate. 
The experimental order was randomized by blind card draw. To 
avoid bag manipulation, a paper label was attached to each drip 
hook. Sampling occurred immediately on commencement of the 
infusion, thereafter every 5 minutes for the first 20 minutes, and 
at 10-minute intervals for the following 70 minutes. Five-milliliter 
samples were collected in barcoded, sterile. plastic laboratory 
test tubes. Potassium concentrations were analyzed within 
2 hours of samples collection. Analysis was performed using a 
SYNCHRON CX 5 System (Beckman Coulter, Fullerton, CA, USA.) 
with a potassium analytical range between 2.0 to 200.0 mmol/
liter. Samples were not diluted. SYNCHRON CX 5 calibration and 
quality control results, performed immediately prior to sample 
analysis, were to be within specified standards for analysis to 
happen. Experiment 1 was repeated one month later, the former 
and latter experiments referred to for example as “Control 1” 
and “Control 2” respectively (Table I). Data was entered into an 
Excel® spreadsheet (Microsoft Excel® for MAC 2011, Microsoft 
Corporation, Redmond, USA) for calculation and graphing of the 
delineated scenarios. To calculate dose, the trapezoid rule was 
applied to the measured potassium concentrations. The primary 
endpoints in Experiment 1 were the concentrations and doses of 
potassium delivered over a 90-minute infusion.
Similar experiments (Experiment 2) investigated maldistribution 
by interrogating the color distribution occurring after 1 ml of 
Table 1: Experiment 1 protocol
Experimental Arm Injection time Solute Bag inversion Timing
Control 1 4 seconds 20 ml 0.9% NaCl No Baseline
Control 2 4 seconds 20 ml 0.9% NaCl No 1 month
Agitate 1 20 seconds 20 ml  15% KCl Yes Baseline
Agitate 2 20 seconds 20 ml  15% KCl Yes 1 month
Slow 1 20 seconds 20 ml  15% KCl No Baseline
Slow 2 20 seconds 20 ml  15% KCl No 1 month
Fast 1 4 seconds 20 ml  15% KCl No Baseline
Fast 2 4 seconds 20 ml  15% KCl No 1 month
NaCl is sodium chloride solution; KCl is potassium chloride solution.
Figure 1: Concentrated potassium chloride box and ampoule indicating 
instructions for dilution before point of care use.
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Bonney’s blue, a dye comprising crystal violet and brilliant green, 
(Hospital Supplies, Pretoria, South Africa) had been added to 
19 ml concentrated 15% potassium chloride or 19 ml of normal 
saline. No formal quantification of this aspect of the study was 
made. Homogenization was evaluated by visual inspection of 
the color distribution of the Bonney’s blue using photographs 
taken with a Panasonic Lumix DMC-FZ18, 18 x Optical Zoom, 
(Matsishita Electric Industrial Company, Osaka, Japan) before and 
5, 30, 60 and 90 minutes after adding concentrated potassium 
chloride and commencing the simulated infusion. This protocol 
was not repeated.
Results 
Experiment 1: Potassium concentrations 
In both the “Control”, and “Agitate” experiments, potassium 
concentrations were constant over the 90-minute experimental 
period, averaging 5.2 and 45.8 mmol/l respectively (Table 2). 
The rate of potassium delivery was constant in the “Control”, and 
“Agitate” experiments.
In both the “Fast” and “Slow” experiments, potassium 
concentrations and delivery rates (Table 2, Figure 2) peaked at 
the five minute measurement, and decreased progressively 
thereafter, becoming clinically indistinguishable from control 
sometime between the 50 to 80 minute measurements. Peak 
potassium concentrations were 165.1 and 268.1 mmol/l  in the 
“Fast” experiments, and 85.2 and 230.1 mmol/l in the “Slow” 
experiments (Table 2). Potassium dose rates peaked during the 
second five minute interval, averaging 9.4 and 7.0 mmol per 
five minutes for the “Slow” and “Fast” experiments respectively 
(Figure 2).  
When considering delivery as a percentage of total available 
potassium, 33 and 25% (representing 15.0 and 11.1 mmol) 
would have been administered with the initial 100 millilitres in 
the Fast and Slow experiments respetively. After 300 millilitres 
of fluid delivery, 71 and 67% of the total available potassium 
represeting 32.0 and 32.3 mmol of potassium in the Fast and 
Slow experiments respectively, would have been administered 
(Figure 3).
Experiment 2: Colour distribution using Bonneys blue dye 
Photographs of stained potassium chloride 5 minutes after 
injection demonstrated a homogenous blue color in the “Control” 
and “Agitate” experiments (Figure 4). In the “Slow” experiment, 
the colour was distributed in the lower half of the Ringer’s lactate 
bag while in the “Fast” experiment, the blue colouration spread 
higher. Sixty minutes after commencing the infusion, the dye in 
Table 2: The measured potassium concentrations (mmol/l) in fluid discharged from each liter Ringer’s Lactate container. The number “1” denotes 
the first performance of the experiment and the number “2” the second performance of the experiment. See “Methods” section for explanation of 
slow, fast agitated and control experiments. The slightly lower oncentration of potasium in the control group is a result of saline dilution. The “0 
minute” measurements that effectively represent infusion set prime, are very close to the 5.3 mmol/l potassium concentrations expected in ringers 
lactate. The higher initial concentration measured in the “fast” experiment was due to air bubbles activating the pump alarm, necessitating flusing of 
the giving set.  
Time 
(mins)
Slow
1
Slow
2
Fast
1
Fast
2
Control
1
Control
2
AgitateAg
1
Agitate
2
0 5.31 5.28 5.27 15.68 5.28 5.28 5.82 5.28
5 85.19 230.05 165.05 268.14 5.18 5.16 53.62 50.70
10 83.39 160.55 134.69 177.77 5.09 5.17 50.21 52.99
15 81.09 127.85 119.34 106.90 5.13 5.18 48.49 52.78
20 80.01 108.61 103.49 40.75 5.15 5.18 47.84 52.64
30 73.45 82.72 65.39 15.72 5.09 5.17 46.63 52.43
40 60.91 36.25 13.96 14.25 5.13 5.13 46.63 52.15
50 44.55 6.81 5.49 13.36 5.09 5.23 46.38 52.43
60 27.82 5.65 5.46 12.53 5.15 5.24 45.95 51.87
70 17.18 5.56 5.42 11.56 5.16 5.19 45.09 52.08
80 7.14 5.56 5.44 10.33 5.13 5.17 44.91 51.39
90 5.54 5.51 5.49 7.87 5.17 5.20 41.03 50.63
Figure 2. Potassium dose rate (mmol per 5 minutes) versus time at an 
infusion rate of 600 ml per hour. In all Fast and Slow experiments, a peak 
in the potassium dose rate was observed at the ten minute interval. 
At peak rates in this graph, more than half an ampoule of concntrated 
potasssium would have been delivered over a five minute period. The 
extremely rapid dose rate decline is indicative of severe maldistribution. 
The similar shape of the curves is indicative of the interactions between 
density and turbulence, these factors promoting maldistribution and 
homogenization respectively. The constant dose rate in the “Agitate” 
and “Control” bags is indicative of potassium homogenization. 
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the “Slow” experiment was completely eliminated while in the 
“Fast” bag, a small amount of dye was still present (Figure 5).
Discussion
Following injection of concentrated potassium chloride into 
suspended, flexible one-liter Ringers lactate infusion bags, 
clinically concerning maldistribution was observed. Fifteen 
minutes after commencing a simulated 600 ml per hour 
infusion, maldistribution would have resulted in fourfold 
greater potassium delivery than if homogenized. This fourfold 
difference in the maldistributed compared to the homogenised 
solutions would have caused 25.4 versus 7.5 mmol of potassium 
to be delivered to a pateint. Such a substantial dose, possibly 
in combination with a low cardiac output, was the likely cause 
of hyperkalemia and cardiac arrest in the index case. Our null 
hypothesis was thus rejected. 
Cognitive psychology categorizes unintentional drug errors 
into firstly, failure to execute a good plan and secondly, correct 
execution of an inappropriate plan.23,29,30 The first type of error is 
defined as either “slips” (lack of attention), or “lapses” (omission 
due to memory failure), occurring during routine tasks requiring 
little cognitive input. The latter type of error are termed “mistakes” 
which occur when a normally good plan is misapplied,23,30 
potassium maldistribution conforming to this definition. 
Remedial guidelines aimed at eliminating concentrated 
potassium errors make little if any mention of maldistribution. 
Research similar to that performed in this study has invariably 
followed unintended hyperkalemia due to maldistribution,31-38 
the first report by Williams in 1973 concurring with this impetus. 
Such experiments (Table III) have typically involved syringing 
(13 to 40 mmol) concentrated potassium into flexible intra-
venous fluid bags. Results generally echo our findings, unmixed 
bags consistently revealing maldistribution with impressive 
peak concentrations (e.g. 93031 and 135132 mmol/liter) and the 
bulk (70 to 80%) of added potassium delivered within 20 minutes 
of the infusion commencing.31,32,36-40 Maldistribution can also 
occur with heparin, insulin,32 chlorthiazide, diphenylhydantion,38 
or magnesium,41 the severity of the latter similar to that observed 
with potassium.41
More rapid injection rates would be expected to induce turbu-
lence and greater homogenization, but this was not observed in 
our experiments. Surprisingly little is known about how injection 
rate affects homogenization as most experiments standardized 
this parameter.31,32,35,37 The data variation resulting from the man-
ual potassium injection in our study is nevertheless illustrative of 
what probably occurs clinically. It also emphasizes maldistribu-
tion is primarily related to difference in density (baricity) of sol-
ute and solvent, hyperbaric solutions gravitating to the bottom 
of the intravenous fluid container. The specific gravity of both 
sodium chloride 0.9% and Ringer’s lactate are 1,0045 g/ml(40) 
while that of 15% potassium chloride is 1,084 to 1,093 g/ml at 
21°C.34,37,39 Anesthesiologists are conversant with baricity, epito-
Figure 3. Percentage of total potassium available in the liter of fluid 
infused versus volume infused. With the worst maldistribution, 
approximately 80% of the available potassium would potentially 
have been delivered to the patient in the first 250 ml of carrier fluid.  
The almost straight line relationships in the Control and Agitated 
experiments indicate a constant potassium infusion rate.
Figure 4. Distribution of potassium chloride stained with Bonney’s 
blue in ringers lactate five minutes after commencing infusion. A 
homogenous blue color is visible in the “Agitate C5’” and “Control D5’” 
experiments. In the “Slow A5’” experiment, the colour was distributed 
in the lower half of the bag while in the “Fast B5’” experiment, the blue 
colouration spread higher.
Figure 5. Distribution of potassium chloride stained with  Bonney’s blue 
in ringers lactate thirty and sixty minutes after commencing infusion 
in the Fast and Slow experiments. Sixty minutes after commencing 
the infusion, the dye in the “Slow A60’” experiment was completely 
eliminated while in the “Fast B60’” bag, a small amount of staining was 
still present
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mized by the directionality of intrathecally administered hyper-
baric local anesthetic solutions.18 Maldistribution has previously 
featured in anesthesia related problems, being blamed for local 
anesthetic neurotoxicity.42,43
Purposeful mixing largely eliminates solute maldistribution. 
One,35 two (this experiment)38,39 three41 and six32, 37  fluid bag 
inversions all effectively homogenized potassium or magnesium 
containing solutions. Manually shaking a hanging bag also proved 
effective.40 Squeezing or adding the potassium solute with the 
initially bag on its side and then hung upright, ameliorates but 
does not eliminate the problem.37,44 Thirteen cycles of normal 
handling, described as a removal of the bag from the drip stand, 
addition of potassium, and return of the bag to the hook, were 
needed to facilitate complete mixing.40 Longer standing times, 
probably due to Brownian motion,37 improve solute and solvent 
mixing by between 10.540 to 50%,37 but on its own, is unreliable.34 
Combining a short (10 second) injection time, horizontal initial 
bag position, and needle parallel rather than at 45° to the long 
axis of the bag afforded the least maldistribution; however 
this combination was still insufficient to guarantee adequate, 
safe mixing.40 Maldistribution is aggravated by longer injection 
ports, short needles, and partial (<1 cm) insertion of the needle 
into the bag.33,35,36 Wave reflection likely explains the good 
homogenization invariably observed after potassium is injected 
into rigid (glass) or semirigid (polyolefin) containers.31,32,35,37,38 
Intravenous resuscitation fluids are seldom presented in glass 
containers.
In the index case, potassium supplementation rate was intend-
ed to be 0.34 mmol/kg/hour, this being at the upper end of 
the Evers and Maze’s(46) recommended range of 0.2 to 
0.4 mmol/kg/hour. Exact infusion rates should be based on serum 
potassium levels and the presence of hypokalemia related com-
plications. Intravenous supplementation at abovementioned 
rates should be accompanied by monitoring of EKG rhythm and 
morphology, and frequent potassium serum concentrations. 
The SYNCHRON CX 5 System used in this study to measure 
potassium concentrations, had a measurement range wide 
enough not to require sample dilution. This avoided error 
magnification, a significant advantage over similar studies. 
Potassium measurement techniques in similar studies have 
included a flame photometer,32,35,38 the former specifying 200-
fold sample dilution, a digital refractometer37, and a potassium 
ion specific electrode requiring 1000 fold dilution.34 Another 
study measured chloride concentrations with a formula used to 
derive potassium concentrations.40  
Various coloured dyes (methylene blue,31 indigo carmine33) have 
been used to visually evaluate potassium distribution. Despite 
objective measurements not clouding our visual assessments, 
distribution of potassium and Bonney’s blue appeared 
inconsistent. This discrepancy imitates that distribution 
depends on the independent densities of solute, an important 
consideration when implementing the potentially valuable 
suggestion of adding dye to indicate solute maldistribution.41 
The potentially valuable suggestion of including coloured 
indicators to solutes needs consideration of their relative 
densities.  
Study limitations include non-standardization of the potassium 
chloride injection rate as we did not have a device capable of 
simulating addition of 20 milliliters of potassium over eiether 
20 or 4 seconds, this necessiating infusion rates of 3600 and 
18000 ml/hour respectively. Nonetheless, this limitation was 
revealing regarding factors influencing solute maldistribution.  
Statistical analysis was not performed as the experiment was 
aimed at reproducing index case events and interrogating 
the hypothesis. Furthermore, the aim was not to perform a 
descriptive, population-based study, but to highlight and 
demonstrate an important issue. The duplicate experiments 
produced close enough results, further experiments were thus 
regarded as superflous, and financial and resource constraints 
also limited study repetitions. The double bag inversion should 
be further investigated as a reliable, simple method of potassium 
and other solute homogenization.
In conclusion, remedial guidelines have hitherto focused 
on eliminating errors of potassium substitution rather than 
maldistribution.21 The potential gravity of concentrated solute 
maldistribution was highlighted by the index case and confirmed 
in the experiment,45 a significant driver of this study being to 
highlight these dangers. To our knowledge, premixed solutions 
specifically for intravenous potassium supplementation are not 
commonly supplied by South African in-hospital pharmacies. 
Physicians and nurses in critical care areas in South Africa 
and possibly many other developing countries, likely still 
mix solutions for potassium supplementation themselves. 
Inversion of intravenous fluid containers at least twice after 
solute addition appears to be a simple and effective method 
of eliminating maldistribution. Other cornerstones of safe 
therapy include not treating mild, uncomplicated hypokalemia, 
and monitoring plasma concentrations and EKG during intra- 
venous potassium administration. Solutions containing 
significant potassium concentrations should ideally have 
their rate regulated with an electronic infusion controller. The 
maximum dose reccomendations of 0.2 to 0.4 mmol/kg/hour 
should be respected.
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